Targeting Transthyretin Amyloidosis in the Eye with Next-Generation Stabilizers: At40 Displays Potent Ttr Stabilization in the Human Vitreous

AuthID
P-00Q-WJD
6
Author(s)
Document Type
Article
Year published
2019
Published
in AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, ISSN: 1350-6129
Volume: 26, Issue: sup1, Pages: 73-74 (2)
Conference
16Th International Symposium on Amyloidosis (Isa), Date: MAR 26-29, 2018, Location: Kumamoto, JAPAN, Sponsors: Pfizer, Alnylam Pharmaceut, Sanofi Genzyme, Prothena, Ionis Pharmaceut, Janssen Pharmaceut Inc, Eidos Therapeut, Takeda Pharmaceut Co Ltd, Nihon Pharmaceut Co Ltd, Sumitomo Dainippon Pharma, GlaxoSmithKline K K, Dojin Mol Technologies Inc, Celgene K K, Roche Diagnost K K, Daiichi Sankyo Co Ltd, Novartis Pharma Co Ltd, Mochida Pharmaceut Co Ltd, Astellas Pharma Inc, Chest M I Inc, Eisai Co Ltd, Otsuka Pharmaceut Co Ltd, Bristol Myers Squibb Co, Fujifilm RI Pharma Co Ltd, Kyowa Hakko Kirin Co Ltd, Eiken Chem Co Ltd, FP Pharmaceut Corp, Bayer Yakuhin Ltd, Japan Blood Prod Org, UCB Japan Co Ltd, Teijin Pharma Ltd, Otsuka Pharmaceut Factory Inc, Cyberdyne Inc, IDS Co Ltd, Boehringer Ingenheim Ltd, AbbVie GK, Sysmex Corp, HouRai Medech Co Ltd, Yamashita Med Instruments Co Ltd, NPO Corp Kibou no Mori
Indexing
Publication Identifiers
Pubmed: 31343304
Scopus: 2-s2.0-85069628713
Wos: WOS:000477775700041
Source Identifiers
ISSN: 1350-6129
Export Publication Metadata
Marked List
Info
At this moment we don't have any links to full text documens.